SAN DIEGO, June 14, 2013 /PRNewswire/ --Elcelyx Therapeutics today announced that the company and principal investigator Ralph A. DeFronzo, M.D. will present posters related to NewMet', a delayed-release formulation of generic metformin, at the 73rd Scientific Sessions of the American Diabetes Association in Chicago, IL. Dr. DeFronzo, Professor of Medicine and Chief of the Diabetes Division at the University of Texas Health Science Center and the Audie L. Murphy Memorial Veterans Administration Hospital, will describe the results of Elcelyx's Phase 2a clinical trial that compared NewMet with generic metformin in patients with Type 2 diabetes. Mark Fineman, Ph.D., Senior Vice President, Research & Development at Elcelyx will present a second poster accepted as a late-breaker that describes a model designed to predict the metformin plasma exposure with NewMet in Type 2 diabetes patients with mild, moderate and severe renal impairment.
The schedule for the NewMet poster presentations at the McCormick Place Convention Center follows:
Dissociation between metformin plasma exposure and its glucose-lowering effect: A novel gut-mediated mechanism of action
- Date and Time: Sunday, June 23, 2013, 12:00 p.m. to 2:00 p.m. CT
- Category: 01-D Clinical Therapeutics/New Technology - Oral Agents
- Poster #: 1087-P
- Presenter: Ralph A. DeFronzo, M.D., University of Texas Health Science Center, San Antonio
Delayed-release metformin may be suitable for use in diabetes patients with renal impairment that are contraindicated for currently available metformin formulations
- Date and Time: Sunday, June 23, 2013, 12:00 p.m. to 2:00 p.m. CT
- Category: 01-D Clinical Therapeutics/New Technology - Oral Agents
- Poster #: 75-LB
- Presenter: Mark Fineman, Ph.D., Elcelyx Therapeutics
About NewMet'
Elcelyx Therapeutics' pharmaceutical product candidate NewMet is a delayed-release formulation of metformin, the foundational treatment for Type 2 diabetes. By redesigning generic metformin to target the lower bowel, NewMet dramatically reduces the amount of active ingredient in the bloodstream while still maintaining metformin's potent glucose lowering benefit. Phase 2a trial results indicate that a significantly lower once-daily dose of NewMet that maintains efficacy may meaningfully reduce metformin's gastrointestinal side effects and eliminate the need for titration to initiate treatment. NewMet's improved safety and tolerability profile may make it appropriate for use by Type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated due to renal impairment. A multicenter U.S. Phase 2b dose-finding clinical trial is fully-enrolled with 240 patients with Type 2 diabetes.
About Elcelyx Therapeutics
Elcelyx Therapeutics develops pharmaceutical and consumer healthcare products based on its proprietary Gut Sensory Modulation (GSM) platform. Pharmaceutical product candidate NewMet' is being developed for use by Type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. In the consumer health area, Elcelyx is developing Lovidia' as a dietary supplement for weight management. These product candidates are backed by rigorous science and clinical data and present near-term, blockbuster commercial opportunities. Elcelyx is based in San Diego, CA. For more information, visit www.Elcelyx.com.
SOURCE Elcelyx Therapeutics
